DOCSLIB.ORG

CAPSULES Composition Packaging 6,15,10,Alu-Alu 10X10,15X15,Alu-Alu

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CAPSULES Composition Packaging 6,15,10,Alu-Alu 10X10,15X15,Alu-Alu CAPSULES Composition Packaging Amoxycillin 250mg DT/500mg 6,15,10,alu-alu Amoxycillin 250mg/500mg, lactic acid bacillus 60 million spores 10x10,15x15,alu-alu Amantadine Hcl 100mg 10 Amoxycillin 250/500mg 10 Amoxycillin 250/500mg, lactic acid bacillus 60 15 million spores Amoxycillin 250/500mg, bromhexine 8mg 15 Amoxycillin 250/500mg, carbocisteine 150mg 15 Amoxycillin 500mg, clavulanic acid 125mg 6 Amoxycillin 250mg, Cloxacillin 250mg 10 Amoxycillin 250mg, Cloxacillin 250mg, lactic 10 acid bacillus 60 /120million spores Amoxycillin 250mg, Cloxacillin 250mg, 15 probenecid 250 mg Ampicillin 250/500mg 30 Ampicillin 250mg, Cloxacillin 250mg, lactic 10 acid spores 60 million Ampicillin 125/250mg, Cloxacillin 125/250mg 10 Artemether 40mg 10x6 Atazanavir 100/200/300/400mg 10/30/60/40 Azithromycin 250mg 6 Cefaclor 250/500mg 10,3 Cefadroxil 250/500mg 10 Cefdinir 300mg 4,6 Cefixime 100/200/400mg 4/6/10x10 Ceftibuten 400mg 5 Cefuroxime 125/250mg, probenecid 250mg 4 Cephalexin 250/500mg 10 Cephalexin 250/500mg, carbocisteine 150mg 4 Cephalexin 250/500mg, carbocisteine 250mg 10 Chloramphenicol 250/500mg 10x10/10x20 Clindamycin hcl 150/300mg 5 Clindamycin hcl 100mg, clotrimazole 100mg 7 Clofazimine 50/100mg 10 Cloxacillin 250/500mg 15 Cycloserine 250mg 6 Didanosine 250/400mg 30 Doxycycline 100mg 30x10 Efavirenz 200/600mg 30,10 Fluconazole 150/200mg 4,1 Ganciclovir 250/500mg 10 Indinavir 400mg 10 Itraconazole 100mg 1x4 Lincomycin 250/500mg 5 Minocycline hcl 50/100mg 6/10/2024 Neomycin sulphate 350mg 10 Nevirapine 200mg 10 Oseltamivir 75mg 10 Ribavirin 100/200mg 4 Rifampicin 150/300/450/600mg 10 Rifampicin 450/600mg, isoniazid 300mg 4 Ritonavir 100mg 60 Ritonavir 33.3mg, Lopinavir 133.3mg 30 Saquinavir 200mg 10 Stavudine 30/40mg 10 Tetracycline hcl 250/500mg 10,4 Oxytetracycline hcl 250mg, thiamine 4 mononitrate 2.5mg, riboflavine 2.5mg, niacinamide 25mg, pyridoxine hcl 0.5mg, calcium pantothenate 5mg, vit B12 3mcg, folic acid 0.375ng Zanamivir 5mg 10 Zidovudine 100mg 10 Alpha-galactosidase 200mg, lactase enzyme 10 7mg, protease enzyme 25mg, amylase enzyme 50mg, lipase enzyme 3mg Alpha-galactosidase 150mg, amylase 50mg, 10 proteases 25mg, lipase 3mg, lactase 7mg Balsalazide 750 mg 10 Cinitapride 3mg, pantoprazole 40mg 10 Dioctyl sod. Sulfosuccinate 100mg 6 Fungal diastase (1:1200) 50 mg, 10 Pepsin(1:3000) 20mg Alpha amylase (1:800) 100mg, Papain 60mg 15 Lipase 10,000 PhEur units, amylase 10 8,000PhEur units, protease 600 PhEur units Fungal diastase 50mg, pepsin 10mg, 10 simethicone 50mg Esomeprazole 40mg, itopride 150mg 10 Esomeprazole 20mg 10 Esomeprazole 40/20mg, domperidone 30mg 10 Fenoverine 100/200mg 10 Lansoprazole 30/15mg 10 Lansoprazole 30/15mg, Domperidone 10 10/30mg Loperamide 2 mg 10 Metoclopramide Hcl 15mg 10 Omeprazole10/ 20/40mg 10x20 Omeprazole 10/20mg, Domperidone 10/30mg 10 Omeprazole 20mg, Domperidone 20mg (SR) 10 Pantoprazole 40 mg, domperidone 30mg 10 (20mg as sustained release+10mg as immediate release) Pantoprazole 20 mg, Domperidone 10mg 10 Pantoprazole 40 mg, itopride hcl 150mg 10 Pantoprazole 40 mg, domperidone 30mg SR 10 Pantoprazole 40 mg 10 Cinitapride 3mg, pantoprazole 40mg 10 Lactobacillus acidophilus 300 million, 10 bifidobacterium longum 150 million, bifidobacterium bifidum 150 million, fructo oligo saccharides 200mg, l-glutamine 100mg, streptococcus themophilus 150 million Lactobacillus acidophilus 0.48 billion, 10 lactobacillus rhamnosus 0.48 billion, bifidobacterium longum 0.48 billion, bifidobacterium bifidum 0.48 billion, saccharomyces boulardil 0.1 billion, streptococcus thermophilus 0.48 billion, fructo oligo saccharides 300mg Fructo oligosaccharide 200ms, L-glutamic 10 100ms, bifidobacterium bifidum 150 ms, bifidobacterium longum 150ms, lactobacillus acidophilus 150 ms, streptococcus thermophilus 150 ms Fructo oligosaccharide 200mg, L-glutamic 10 100mg, bifidobacterium bifidum 150 ms, bifidobacterium longum 150ms, lactobacillus acidophilus 300 ms, streptococcus thermophilus 150 ms Rabeprazole 20/40 mg 10 Rabeprazole 20mg+ Domperidone 30 mg SR 10 Rabeprazole 20mg+ Domperidone 30 10 mg(10mg as immediate release and 20 mg as sustained release) Rabeprazole 20mg, Domperidone 10 mg 10 Rabeprazole 20 mg, itopride 150 mg 10 Rabeprazole 20 mg(EC), itopride 150 mg (SR) 10 Itopride Hcl 150mg SR, Rabeprazole 20mg 10 Rabeprazole 20 mg, itopride 150 mg SR 10 Racecadotril 100 mg 10 Racecadotril 50mg, lyophilized saccharomyces 10 boulardii 282.5mg, lactic acid bacillus 100 million spores Saccharomyces boulardii 100 /250/500mg 10 Levocetirizine 5mg, ambroxol 75mg 10 Levocetirizine 5mg, pseudoephedrine 120mg 10 sustained release Levocetirizine dihcl 5mg, ambroxol hcl 75mg 10 Diphenhydramine 25/50mg 10,50 Valsartan 80mg, nebivolol 5mg 10 Valsartan 80mg, ramipril 2.5/5mg 10 Valsartan 80mg, s-amlodipine 2.5mg 10 Valsartan 40/80/160mg 10 Ramipril 1.25/2.5/5/10mg 10 Phenoxybenzamine 10mg 5x10 Nifedipine 10/20mg, Atenolol 50mg 10 Nifedipine 20mg(SR), Atenolol 50mg 10 Nifedipine 10/2030mg (Retard) 10 Nifedipine 5/10mg 30 Nicorandil 5/10mg 10 Mexiletine hcl 50/150mg 10 Metoprolol 25 /50mg 10 Metoprolol succinate 25mg, amlodipine 5mg 10 Metoprolol 25/50 mg extended release 10 Isosorbide-5-mononitrate 30/60 mg, Aspirin 75 10 mg Isosorbide-5-mononitrate 30 /60mg 10 Isosorbide dinitrate 5/10/20/40 mg 25 Glyceryl trinitrate 2.5/6.2mg 25 Dried extract of Ginkgo biloba 60mg equiv. To 10 Ginkgoflavonglycosides 14.4mg Diltiazem 30/60/90/120mg 10 Diltiazem 30/60/90/120mg controlled release 10 Cyclandelate 200/400mg 10 Clopidogrel 75mg, Aspirin 75/150mg 10 Calcium dobesilate monohydrate 500 mg, 10 Docusate sodium 100mg Calcium dobesilate monohydrate 500 mg 10 Atenolol 50mg, thiazide 12.5mg, ramipril 5mg, 10 simvastatin 20mg, aspirin 100mg Atenolol 50mg, nifedipine 10/20mg 10 Amlodipine 5mg, enalapril 2.5/5mg 10 Amlodipine 5mg, Atenolol 50mg, Aspirin 10 100mg Acetazolamide 250mg (SR) 10 Alprazolam SR 0.5mg, Sertraline 25/50mg 10 Amantadine Hcl 100mg 10 Amantadine 100mg 10 Atomoxetine Hcl 10/18/2525mg 10 Benfotiamine 100mg, Methylcobalamine 10 1000mcg, inositol 100mg, alpha lipoic acid 100mg, pyridonxine hcl 1.5mg, folic acid 0.75mg Divalproex sodium125/250/ 500mg 10 Duloxetine Hcl 20/30/40mg 10 Duloxetine Hcl 20/30mg, mecobalamin 750mg 10 Flunarizine 5/10mg 10 Fluoxetine hcl 20/60mg 25 Flurazepam Hcl 15mg 10 Gabapentin 100/300/400/600/800mg 10 Levodopa 100mg, Benserazide hcl 28.5mg 10 Loxapine 10/25mg 10 Methylcobalamin 1500mcg, alpha lipoic acid 10 100mg, multivitamin Mecobalamin 1500mcg, folic acid 1.5mg, 10 alpha lipoic acid 100mg, vit B6 3mg Methylcobalamin, pyridoxine hcl, DHA, folic 10 acid Methylcobalamin 1500mcg, benfotiamine 10 75mg, chromium polynicotinate 200mcg, pyridoxine 3mg, folic acid 1.5mg Nitrazepam 5/10mg 10 Piracetam25/30/150/ 400mg 10 Piracetam 800mg, mecobalamin 1000mcg 10 Propranolol hcl 40/80/60 mg 10 Venlafaxine 25/37.5/75/150mg 10 Zaleplon 5/10mg 10,7 Ziprasidone 20/40/60/80mg 10 Testosterone 40mg 30 Stanozolol 2mg 10 Progesterone 100/200/400mg 10 Pioglitazone 15mg, glimepiride 1/2mg 10 Glucomannan 500mg 10 Danozol 50/100/200mg 10 Chromium picolinate 500mcg, folic acid 1mg, 15 vit B12 15mcg, vit B6 3mg, zinc sulphate monohydrate 27.5mg .
Load more

Recommended publications
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • A Four-Country Comparison of Healthcare Systems, Implementation
    Neurogastroenterology & Motility Neurogastroenterol Motil (2014) 26, 1368–1385 doi: 10.1111/nmo.12402 REVIEW ARTICLE A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders A report of the Rome Foundation Working Team on cross-cultural, multinational research M. SCHMULSON,* E. CORAZZIARI,† U. C. GHOSHAL,‡ S.-J. MYUNG,§ C. D. GERSON,¶ E. M. M. QUIGLEY,** K.-A. GWEE†† & A. D. SPERBER‡‡ *Laboratorio de Hıgado, Pancreas y Motilidad (HIPAM)-Department of Experimental Medicine, Faculty of Medicine-Universidad Nacional Autonoma de Mexico (UNAM). Hospital General de Mexico, Mexico City, Mexico †Gastroenterologia A, Department of Internal Medicine and Medical Specialties, University La Sapienza, Rome, Italy ‡Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India §Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea ¶Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA **Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA ††Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ‡‡Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Key Messages • This report identified seven key issues related to healthcare provision that may impact how patients with FGIDs are investigated, diagnosed and managed. • Variations in healthcare provision around the world in patients with FGIDs have not been reviewed. • We compared four countries that are geographically and culturally diverse, and exhibit differences in the healthcare coverage provided to their population: Italy, South Korea, India and Mexico. • Since there is a paucity of publications relating to the issues covered in this report, some of the findings are based on the authors’ personal perspectives, press reports and other published sources.
    [Show full text]
  • Clinical Trial Year Purpose Results Link Source Effects of Alverine
    Clinical Trial Year Purpose Results Link Source The intestinal mechanoreceptors located at the endings of type C vagal fibres responded mainly to mechanical stimuli (distension and Aliment Effects of alverine citrate on cat intestinal contraction), but also responded to chemical substances https://onlinelibrary.wiley.com/ To determine whether alverine citrate acts (cholecystokinin and substance P). The most conspicuous effect of Pharmacology and mechanoreceptor responses to chemical and 2001 doi/abs/10.1046/j.1365- on the vagal sensory endings. alverine (2 mg/kg) was that it significantly inhibited the pattern of Therapeutics mechanical stimuli 2036.1999.00497.x vagal activity produced in response to either cholecystokinin (AP&T) (5–10 μg/kg), substance P (5–10 μg/kg) or phenylbiguanide (5–10 μg/kg), a 5‐HT3 receptor agonist. This study was designed to evaluate the Royal Pharmaceutical pharmacological properties of alverine citrate Results suggest that 5‐HTP‐induced rectal hypersensitivity Rectal antinociceptive properties of alverine in a rat model of rectal hyperalgesia induced by https://onlinelibrary.wiley.com/doi Society of Great involves 5‐TH1A receptors and that alverine citrate acts as a citrate are linked to antagonism at the 5- 2001 5‐HTP (5‐HT precursor) and by a selective /epdf/10.1211/002235701177778 Britain, (Journal of selective antagonist at the 5‐HT1A receptor subtype to block 5‐HT1A agonist (8‐OH‐DPAT) and to 3 Pharmacy & HT1A receptor subtype both 5‐HTP and 8‐OH‐DPAT‐induced rectal hypersensitivity compare this activity with a reference Pharmacology) 5‐HT1A antagonist (WAY 100635) (JPP) British We have investigated the mechanisms Alverine suppressed contractions produced by high K (40 mM) Pharmacological underlying the paradoxical ability of the or ACh (10 μM), without affecting electrical responses and https://bpspubs.onlinelibrary.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0203190 A1 Burgard Et Al
    US 20050203190A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0203190 A1 Burgard et al. (43) Pub. Date: Sep. 15, 2005 (54) METHODS OF TREATING Related U.S. Application Data GASTRONTESTINAL TRACT DISORDERS USING SODIUM CHANNEL MODULATORS (62) Division of application No. 10/769,071, filed on Jan. 30, 2004. (75) Inventors: Edward C. Burgard, Chapel Hill, NC (US); Steven B. Landau, Wellesley, (60) Provisional application No. 60/443,731, filed on Jan. MA (US); Matthew Oliver Fraser, 30, 2003. Provisional application No. 60/443,730, Apex, NC (US) filed on Jan. 30, 2003. Provisional application No. 60/480,565, filed on Jun. 20, 2003. Provisional appli cation No. 60/480,598, filed on Jun. 20, 2003. Pro Correspondence Address: visional application No. 60/495,958, filed on Aug. 18, ALSTON & BIRD LLP 2003. BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000 Publication Classification CHARLOTTE, NC 28280-4000 (US) (51) Int. Cl. ............................................ A61K 31/137 (52) U.S. Cl. .............................................................. 514/649 (73) ASSignee: Dynogen Pharmaceuticals, Inc., Waltham, MA (57) ABSTRACT The invention relates to methods of using Sodium channel (21) Appl. No.: 11/057,024 modulators, particularly TTX-R sodium channel modulators and/or activity dependent Sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflam (22) Filed: Feb. 11, 2005 matory bowel disorders and irritable bowel syndrome. Patent Application Publication Sep.15, 2005 Sheet 1 of 2 US 2005/0203190 A1 Figure 1. A. lamotrigine Control Control 26A750pA fastslow 5ms slow fast 100 s to 80 is 60 s 5(9 40 5 a S.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (NICE). Clinical Practice Guideline: Irritable Bowel Syndrome in Adults
    Clinical practice guideline Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care National Collaborating Centre for Nursing and Supportive Care commissioned by National Institute for Health and Clinical Excellence February 2008 Irritable bowel syndrome: full guideline Page 1 of 554 National Collaborating Centre for Nursing and Supportive Care This guideline was developed by the National Collaborating Centre for Nursing and Supportive Care (NCCNSC) on behalf of the National Institute for Health and Clinical Excellence (NICE). The guideline was commissioned and funded by NICE and developed in accordance with NICE processes and methodologies. Based at the Royal College of Nursing, the NCCNSC is a partnership of organisations brought together for the purposes of supporting the development of NICE clinical practice guidelines. The partnership is comprised of representatives from the following organisations: • Centre for Evidence-Based Medicine, University of York • Clinical Effectiveness Forum for Allied Health Professions • Healthcare Libraries, University of Oxford • Health Economics Research Centre, University of Oxford • Royal College of Nursing • UK Cochrane Centre. Disclaimer As with any clinical practice guideline, the recommendations contained in this guideline may not be appropriate in all circumstances. A limitation of a guideline is that it simplifies clinical decision- making (Shiffman 1997). Decisions to adopt any particular recommendations must be made by practitioners in the
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Effect of Antispasmodic Agents for the Treatment of Irritable Bowel Syndrome
    PHARMACOTHERAPEUTICS pISSN 1975-8456 / eISSN 2093-5951 J Korean Med Assoc 2018 July; 61(7):428-434 https://doi.org/10.5124/jkma.2018.61.7.428 과민성 장증후군 치료에서 진경제의 효과 이 상 헌ㆍ지 삼 룡 | 인제대학교 의과대학 부산백병원 내과 Effect of antispasmodic agents for the treatment of irritable bowel syndrome Sang Heon Lee, MD · Sam Ryong Jee, MD Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea Antispasmodics are effective in reducing abdominal pain and controlling spasm. Irritable bowel syndrome (IBS) patients have characteristic key factors such as intestinal motility disorder and visceral hypersensitivity. So antispasmodics have been used in the treatment of IBS for decades. Mebeverine blocks intestinal peristalsis but are not significantly better than placebo. Alverine citrate combined with simethicone is effective treatment option in IBS. Otilonium and pinaverium bromide are poorly absorbed agents, so they have mostly local effect with minimal systemic adverse events. Phloroglucinol controls acute exacerbation of abdominal pain effectively. Tiropramide reduce abdominal discomfort without serious adverse events. Fenoverine control spasm in spastic colon but does not affect normal contraction. Trimebutine have dual actions that it inhibits hyperactive colon and activates hypomotile colon. Each drug has advantages and disadvantages. Antispasmodics are considered as the first treatment option of pain-dominant IBS. Key Words: Parasympatholytics; Abdominal pain; Irritable bowel syndrome 서론 2005년 Cochrane 문헌고찰에서 일부 진경제는 복통과 전 반적인 증상 호전에 효과가 있다고 하였는데 약한 증거수 과민성 장증후군은 이전에는 ‘경련성 대장’이라고 불리 준이었다[4]. 2006년 유럽에서 시행한 체계적 문헌고찰에 었다. 그 뜻은 경련이 증상을 일으킨다는 뜻이다[1]. 지난 수 서는 9개의 위약군대조시험들이 표준화된 진단기준이 결여 십 년 동안 과민성 장증후군 환자에게 진경제를 사용하고 있 되어 있다는 제한점을 발견하였다[5].
    [Show full text]
  • Microsoft Word
    AUTORISES INTERDITS AC. ACETYLSALICYLIQUE AC. MEFENAMIQUE AC. CLAVULANIQUE AC. NALIDIXIQUE AC. FUSIDIQUE AC. PIPEMIDIQUE AC. NIFLUMIQUE AC. PIROMIDIQUE AC. OXOLINIQUE ACITRETINE AC. TIAPROFENIQUE ADRAFINIL AC. TIENILIQUE ALCOOL AC. TRANEXAMIQUE ALIZAPRIDE ACAMPROSATE ALLOPURINOL ACEBUTOLOL ALMINOPROFENE ACETAZOLAMIDE ALPRAZOLAM ACICLOVIR ALVERINE ACTH AMBROXOL ADRENALINE AMIDOPYRINE ALFENTANIL AMINEPTINE ALFUZOSINE AMINOGLUTHETIMIDE ALIMEMAZINE AMIODARONE AMANTADINE AMISULPRIDE AMFEPRAMONE AMOBARBITAL AMIKACINE ANDROGENES AMILORIDE ARTICAINE AMITRIPTYLINE ASTEMIZOLE AMLODIPINE BACLOFENE AMOXAPINE BARBITURIQUES AMOXICILLINE BENFLUOREX AMPHOTERICINE B BENZBROMARONE APTOCAINE BENZYL THIOURACILE ATENOLOL BEPRIDIL ATRACURIUM BETAHISTINE ATROPINE BIPERIDENE AZATHIOPRINE BISOPROLOL BENAZEPRIL BROMOCRIPTINE BENSERAZIDE BUPIVACAINE (*) BETA-ALANINE BUSPIRONE BETAXOLOL CAPTOPRIL BEZAFIBRATE CARBAMAZEPINE BLEOMYCINE CEFACLOR BROMAZEPAM CEFPODOXIME BROMURE CEFUROXIME BUFLOMEDIL CHLORAMPHENICOL BUPRENORPHINE CHLORMEZANONE BUTACAINE CHLOROQUINE (*) BUTYLHYOSCINE CIBENZOLINE CARBIMAZOLE CICLETANINE CARPIPRAMINE CIPROFIBRATE CEFIXIME CLINDAMYCINE CEFOTAXIME CLOBAZAM CEFTAZIDIME CLOFIBRATE CEFTRIAXONE CLOMETHIAZOLE CELIPROLOL CLOMIFENE CERIVASTATINE CLONIDINE CETIRIZINE CLORAZEPATE CHLORAL HYDRATE CLOTIAZEPAM CHLORDIAZEPOXIDE CYCLOPHOSPHAM 1 DE CHLORPROMAZINE CYPROTERONE CICLOSPORINE DANAZOL CILAZAPRIL DAPSONE CIMETIDINE DENORAL® CIPROFLOXACINE DEXFENFLURAMINE CISAPRIDE DEXTROMORAMIDE CITALOPRAM DEXTROPROPOXYPHENE CLARITHROMYCINE DIAZEPAM CLIDINIUM DIHYDRALAZINE
    [Show full text]
  • Bulking Agents, Antispasmodics and Antidepressants for the Treatment of Irritable Bowel Syndrome (Review)
    Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome (Review) Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 3 http://www.thecochranelibrary.com Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 4 Figure1. ..................................... 7 DISCUSSION ..................................... 11 AUTHORS’CONCLUSIONS . 13 ACKNOWLEDGEMENTS . 13 REFERENCES ..................................... 14 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 83 Analysis 1.1. Comparison 1 Bulking agents: Abdominal pain, Outcome 1 Comparing nr(%) of successfully treated IBS patients..................................... 89 Analysis 1.2. Comparison 1 Bulking agents: Abdominal pain, Outcome 2 Comparing scores on abdominal pain in IBS patients..................................... 90 Analysis 2.1. Comparison 2 Bulking agents: Global assessment, Outcome 1 Comparing nr(%) of successfully
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
    US 2015.0050713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov et al. (43) Pub. Date: Feb. 19, 2015 (54) TECHNOLOGY FOR THE PREPARATION OF Publication Classification MCROPARTICLES (51) Int. Cl. (71) Applicant: Ansun Biopharma, Inc., San Diego, CA CI2N 9/96 (2006.01) (US) CI2N 7/00 (2006.01) CI2N IS/II3 (2006.01) (72) Inventors: Michael P. Malakhov, San Francisco, C07D 305/.4 (2006.01) CA (US); Fang Fang, Rancho Santa Fe, C07K 4/765 (2006.01) CA (US) C07K9/00 (2006.01) (52) U.S. Cl. CPC ................ CI2N 9/96 (2013.01); C07K 14/765 (21) Appl. No.: 14/341,502 (2013.01); C07K9/008 (2013.01): CI2N 15/113 (2013.01); C07D 305/14 (2013.01); (22) Filed: Jul. 25, 2014 CI2N 7/00 (2013.01); C12N 2770/00051 (2013.01) O O USPC ........... 435/188: 530/363; 530/350, 530/367; Related U.S. Application Data 530/385:536/16.8; 536/13.7: 540/336; 530/317; (63) Continuation of application No. 13/874,424, filed on 536/24.5; 530/328; 552/203; 549/510; 435/238 Apr. 30, 2013, now abandoned, which is a continuation (57) ABSTRACT of application No. 13/250,653, filed on Sep. 30, 2011, Mi h duced b tacti lution of a now abandoned, which is a continuation of application 1crospneres are produced by contacting a sol No. 12/179.520, filed on Jul 24, 2008, now aban- macromolecule or small molecule in a solvent with an ant1 doned sa- 1 ws s s Solvent and a counterion, and chilling the solution.
    [Show full text]